Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00223691 · ClinicalTrials.gov registry record · Phase 1
Treatment of Orthostatic Hypotension in Autonomic Failure
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 389
- Enrollment target
NCT00223691: Completed Phase 1 study, sponsored by Vanderbilt University.
NCT00223691 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 389 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (548% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00223691, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 389 participants
- Enrollment target
Study Summary
The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.
Interventions
- DRUG Pyridostigmine Bromide
- DRUG Atomoxetine
- DRUG Yohimbine
- DRUG Midodrine HCl
- DRUG Acarbose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2002-03 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
What the finished NCT00223691 record still lists
NCT00223691 is an interventional study that assigns participants to a tested intervention. The registered 389 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (548% higher).
The record links to 0 conditions, and to 5 interventions - of which Pyridostigmine Bromide is the first listed.
NCT00223691 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00223691 about?
NCT00223691 is a clinical study titled "Treatment of Orthostatic Hypotension in Autonomic Failure". The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also al...
What is the current status of trial NCT00223691?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 389 participants. The study started on 2002-03. Estimated completion is 2017-01.
What interventions are being tested in trial NCT00223691?
The interventions under investigation include: Pyridostigmine Bromide (DRUG), Atomoxetine (DRUG), Yohimbine (DRUG), Midodrine HCl (DRUG), Acarbose (DRUG).
Who is sponsoring clinical trial NCT00223691?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00223691's enrollment target sits among peer trials
389 79th of 2000 higher than 1,922 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05431088 · 389 participants · Phase 2
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia